Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kytopen Names Michael Chiu CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Kytopen Names Michael Chiu CEO

Chiu has a proven track record in fundraising, product development, and marketing launches.

By: Anthony Vecchione

Kytopen, a biotechnology company that develops and markets advanced cell engineering solutions, appointed Michael Chiu, Chief Executive Officer. An entrepreneurial leader with extensive experience in building and commercializing new technologies, Chiu brings a proven track record in fundraising, product development, and marketing launches. Chiu succeeds Paulo Garcia, one of the company’s co-founders, who will continue as an advisor.

Chiu joins Kytopen at the time of its accelerated roll-out of the Flowfect technology to high-profile academic medical centers in the U.S. Prior to this, he was the CEO of Erbi Biosystems, Inc. Earlier in his career, Chiu was a chief technology officer and senior executive with several high-tech companies, including Automation Engineering Inc., Trophos Energy, and Teradyne.

Paul Wotton, Kytopen’s chairman, said, “Kytopen’s suite of genome engineering tools has demonstrated exceptional performance, prompting the expansion and delivery of this transformative technology for wider adoption. Dr. Chiu’s record of accomplishment in successfully commercializing life science instrumentation is a perfect fit for Kytopen’s next stage of growth.”

Chiu said, “Kytopen’s platform and products have transformative potential to redefine the discovery and manufacture of the next generation of living medicines. As global demand for these life-saving cell therapies grows, cost, labor, and time-to-market challenges must be addressed. The growing number of Flowfect Discover systems at leading academic medical centers and industry partners will accelerate work at the leading edges of this exciting field. I’m excited to work with Kytopen’s talented team to expand the access and impact of our scalable, non-viral gene delivery platform for discovering, developing, and manufacturing new therapies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics